Neurocrine Biosciences
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$131.84
FAIR PRICE
$110.90
MARGIN
$20.94
NOW AVAILABLE
Get notified when NBIX's fair price changes
Push notifications when NBIX's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels and strong profitability, but volatile earnings pattern and expensive valuation relative to fundamentals.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$88.72
Fair price × 0.80
DISTANCE
32.7%
Price to entry level
At the current price of $131.84, NBIX trades 32.7% above the conservative entry level of $88.72. This entry level represents a 20% margin of safety below the calculated fair price of $110.90 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate NBIX's fair price
Neurocrine Biosciences's fair price of $110.90 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $131.84, NBIX trades 15.9% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting NBIX's risk profile.
RELATIVE · 30%
Comparing NBIX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for NBIX, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate NBIX's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for NBIX.
Explore on BuliosFAQ
What is the fair price of NBIX?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Neurocrine Biosciences is $110.90. At the current market price of $131.84, NBIX trades 15.9% above its calculated fair value.
Is NBIX overvalued or undervalued?+
Neurocrine Biosciences is currently overvalued based on our valuation model. The stock trades at $131.84, which is 15.9% above the fair price of $110.90. The P/E ratio of 28.1x is a key metric in the valuation.
What is the margin of safety for NBIX?+
With a 20% margin of safety applied to the fair price of $110.90, the conservative entry level for NBIX is $88.72. At the current market price of $131.84, the stock trades 32.7% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is NBIX's fair price updated?+
We update fair price calculations for NBIX daily after market close. The current fair price of $110.90 incorporates the latest market data and sector multiples.
What factors affect NBIX's fair price calculation?+
NBIX's fair price of $110.90 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 28.1x, ROE of 17.7%.
Is NBIX a good buy right now?+
At $131.84, NBIX trades 15.9% above our fair value estimate of $110.90. The stock is currently overvalued. ROE stands at 17.7% (strong). Fair Price Index provides valuation data — always do your own research before investing.
Does NBIX pay dividends?+
NBIX does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.